Iradimed (IRMD) Competitors

Envista (NYSE:NVST) and Iradimed (NASDAQ:IRMD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, community ranking, dividends, risk and analyst recommendations.

Do analysts recommend NVST or IRMD?

Envista presently has a consensus target price of $20.18, indicating a potential upside of 22.70%. Iradimed has a consensus target price of $72.00, indicating a potential upside of 36.17%. Given Iradimed's stronger consensus rating and higher probable upside, analysts plainly believe Iradimed is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	2 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.07
Iradimed	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is NVST or IRMD more profitable?

Iradimed has a net margin of 26.26% compared to Envista's net margin of -44.56%. Iradimed's return on equity of 24.12% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	-44.56%	3.86%	2.21%
Iradimed	26.26%	24.12%	21.20%

Does the MarketBeat Community favor NVST or IRMD?

Iradimed received 225 more outperform votes than Envista when rated by MarketBeat users. Likewise, 65.49% of users gave Iradimed an outperform vote while only 33.33% of users gave Envista an outperform vote.

Company	Underperform	Outperform
Envista	Outperform Votes 35 33.33%	Underperform Votes 70 66.67%
Iradimed	Outperform Votes 260 65.49%	Underperform Votes 137 34.51%

Do insiders and institutionals have more ownership in NVST or IRMD?

92.3% of Iradimed shares are owned by institutional investors. 1.3% of Envista shares are owned by company insiders. Comparatively, 37.1% of Iradimed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has more risk & volatility, NVST or IRMD?

Envista has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Which has better valuation and earnings, NVST or IRMD?

Iradimed has lower revenue, but higher earnings than Envista. Envista is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.51B	1.11	-$1.12B	-$6.49	-2.53
Iradimed	$73.24M	9.18	$19.23M	$1.50	35.25

Does the media prefer NVST or IRMD?

In the previous week, Envista had 5 more articles in the media than Iradimed. MarketBeat recorded 12 mentions for Envista and 7 mentions for Iradimed. Iradimed's average media sentiment score of 0.91 beat Envista's score of 0.15 indicating that Iradimed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envista	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Iradimed	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Iradimed beats Envista on 14 of the 18 factors compared between the two stocks.